Fly News Breaks for February 5, 2020
Feb 5, 2020 | 07:39 EDT
Raymond James analyst Lawrence Keusch maintained a Strong Buy rating on Zimmer Biomet and raised his price target to $190 from $170 after the company reported "solid" Q4 results that support a continued turnaround with new product launches and management execution. A restructuring plan was announced, which targets at least 30% OM for 2023 vs. 27.4% in 2019, another positive as management targets inefficiencies, Keusch tells investors in a research note.
News For ZBH From the Last 2 Days
There are no results for your query ZBH